Investment case
United Therapeutics Corporation
UTHR · 15 developments mapped · last assessed 2026-09-14
Market Ontology has mapped 15 macro, policy, and market developments to United Therapeutics Corporation since 2026-09-03. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for UTHR yet, so no modelled value is shown. The UTHR valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run UTHR on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Open question
Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Patent Fight Continues
Direct competition, patent litigation outcome, market share defense
· Moves market share retention for existing pah therapies, pricing power for existing pah therapies, operating expense trajectory (legal costs)
What changed, by assumption
- 2026-09-14Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Patent Fight Continues
- 2026-09-12Liquidia surpasses 5,000 Yutrepia patients as United Therapeutics litigation looms
- 2026-09-13Liquidia Surpasses 5,000 Yutrepia Patient Starts Amid United Therapeutics Patent Battle
- 2026-09-12Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Patent Battle Persists
- 2026-09-12Liquidia crosses 5,000 Yutrepia patients amid United Therapeutics patent fight
- 2026-09-14Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Litigation Hangs
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-14 | Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Litigation Hangs | mixed | 1-3m | 0.60 |
| 2026-09-14 | Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Patent Fight Continues | mixed | 3-12m | 0.70 |
| 2026-09-13 | Liquidia Surpasses 5,000 Yutrepia Patients Amid United Therapeutics Lawsuit | mixed | 3-12m | 0.60 |
| 2026-09-13 | Liquidia Surpasses 5,000 Yutrepia Patients Amid United Therapeutics Patent Suit | mixed | 3-12m | 0.60 |
| 2026-09-13 | Liquidia Surpasses 5,000 Yutrepia Patient Starts Amid United Therapeutics Patent Battle | mixed | 3-12m | 0.70 |
| 2026-09-12 | Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Patent Battle Persists | mixed | 1-3m | 0.70 |
| 2026-09-12 | Liquidia reaches 5,000 Yutrepia patients as United Therapeutics litigation weighs | mixed | 3-12m | 0.60 |
| 2026-09-12 | Liquidia Surpasses 5,000 Yutrepia Starts as United Therapeutics Patent Battle Weighs on Stock | mixed | 3-12m | 0.50 |
| 2026-09-12 | Liquidia reaches 5,000 Yutrepia patients amid United Therapeutics patent litigation | mixed | 1-3m | 0.60 |
| 2026-09-12 | Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Litigation Continues | mixed | 1-3m | 0.60 |
| 2026-09-12 | Liquidia surpasses 5,000 Yutrepia patients as United Therapeutics litigation looms | mixed | 1-3m | 0.60 |
| 2026-09-12 | Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Patent Litigation Lingers | mixed | 3-12m | 0.50 |